Why is the CSL share price up 11% in a month?

The CSL share price continued to climb today and is flush with green for the month. Here's why.

| More on:
A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares continued their recent climb today to finish up 0.38% to $293.81 
  • The CSL share price has moved northwards by more than 11% over the past four weeks 
  • Several top brokers rate the ASX biotech share as a buy with 12-month price targets in the $300s 

CSL Limited (ASX: CSL) shares continued their recent climb today, up 0.38% to $293.81 at the market close.

The ASX biotech behemoth is up by more than 11% in the past four weeks. That performance is well beyond the S&P/ASX All Ordinaries Index (ASX: XJO), which is down about 1% over the same period.

Let's take a look at what's behind this share price movement for CSL.

Is the CSL share price rising on momentum?

CSL hasn't released any price-sensitive news to the market since 12 May. So it's certainly not company news that is motivating ASX investors to buy the blue-chip share.

However, CSL has attracted plenty of broker backing over the past month. Perhaps this has inspired new investor confidence.

In addition, the CSL share price has been weak for a while and remains well off its pre-COVID highs.

It was always only a matter of time before investors bought back into CSL, as the impact of COVID dies down.

After all, CSL is the epitome of quality and a quintessential blue-chip darling on the ASX. It's currently the third-largest company in the ASX 200 with a market capitalisation of $141 billion.

So, maybe investors have decided now is the time?

What are the brokers saying about CSL?

My Fool colleague James reports today that Morgan Stanley has retained its overweight rating on CSL with a share price target of $312. Macquarie also says buy with the same price target.

Citi also has a buy rating with a more ambitious share price target of $330 for CSL.

Citi analysts commented:

With plasma collections now back to pre-pandemic levels, we expect the market to shift its focus to the strong underlying plasma product demand. This should lead to strength in the CSL share price.

Last week, fellow Fool Tony Yoo also reported that 12 out of 13 analysts rate CSL a buy, according to CMC Markets. Ten of those 12 call it a strong buy.

The pandemic impact on the CSL share price

CSL is a global biotechnology company that manufactures biotherapies and vaccines.

Overall, CSL was a COVID-19 loser. In the initial pandemic market crash of 2020, CSL shares fell from around $336 in February to about $270 in March. As the pandemic rolled on, CSL shares went lower to about $250 in March 2021. They returned to the same level in February this year.

This happened because CSL relies on blood plasma donations to develop its medicines and vaccines. Lockdowns around the world made this exceptionally difficult. That was a bit of a problem given that CSL's blood plasma division generates 70% of its revenue.

Things have changed

As my Fool colleague Monica reported in May, plasma collections are now roughly back to pre-pandemic levels. CSL is also using new technology to reduce the time it takes to donate plasma by 30%.

At the moment, CSL is awaiting the finalisation of its acquisition of Swiss giant Vifor Pharma AG.

Vifor is a leading global producer of products to treat kidney disease and iron deficiency. CSL expected to close the $17 billion deal in June but told the ASX in May that there would be a delay.

In a statement, CSL said it "expects the regulatory approval process to take a few more months".

Regardless, the Vifor deal represents a synergistic expansion that bodes well for the CSL share price.

As we reported, the Vifor acquisition is "expected to be low-to-mid teens NPATA per share accretive in the first full year of CSL ownership, including full run rate cost synergies".

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor Bronwyn Allen has positions in CSL Ltd. and Macquarie Group Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »